In Eurasia, Europe, Israel and Macau
Suven Life Sciences announced that the grant of one (1) product patent from Eurasia (22043), one (1) product patent from Europe (2521714), one (1) product patent from Israel (201491) and one (1) product patent from Macau (J/001840) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Powered by Capital Market - Live News
